Clinical Trial Update: A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours [Phase 1, Phase 2]

View source ↗

Summary

Ipsen is conducting a Phase 1/2 study of IPN60300 to evaluate safety, tolerability, PK/PD, immunogenicity, and antitumor activity in adults with locally advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• IPN60300

Snippet

Sponsor: Ipsen | Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING